Edoxaban in cardiovascular disease management: Review
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY(2022)
摘要
In the past decade, direct oral anticoagulants (DOACs) have transformed the world of anti-thrombotic therapy. Edoxaban is the most recently approved DOAC. Though intended for use primarily in stroke prevention, it has found applications in various other conditions including thromboembolic and peripheral arterial disease. This review aims to provide a detailed outline of the growing indications, evidence for use in special populations, pharmacogenetics and side-effect profile of edoxaban.
更多查看译文
关键词
anticoagulation, atrial fibrillation, bleeding, DOACs, DVT, PE, edoxaban, thrombosis
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要